{"prompt": "['MCW', 'OUTPATIENT', 'VYXEOS', 'TRIAL', 'CTCAE grade', 'Relationship to CPX-351 and outpatient setting (outpatient vs. inpatient)', 'Expectedness', 'Any clinical action taken or planned', 'Outcome (if known)', '6.8 Unanticipated Problem Involving Risk to Subject or Other (UPIRSO)', 'The Office for Human Research Protections (OHRP) considers unanticipated problems involving risks to', 'subjects or others to include, in general, any incident, experience or outcome that meets all of the', 'following criteria:', 'Unexpected in terms of nature, severity or frequency given (a) the research procedures that are', 'described in the protocol-related documents, such as the Institutional Review Board (sIRB)-approved', 'research protocol and informed consent document; and (b) the characteristics of the subject', 'population being studied;', 'Related or possibly related to participation in the research (\"possibly related\" means there is a', 'reasonable possibility that the incident, experience or outcome may have been caused by the', 'procedures involved in the research); and', 'Suggests that the research places subjects or others at a greater risk of harm (including physical,', 'psychological, economic, or social harm) than was previously known or recognized.', 'UPIRSO Reporting Responsibilities', \"Note - it is ultimately the MCW principal investigator's (sponsor) responsibility to determine if an event\", 'is a UPIRSO or SUSAR from all internal and external safety reports, taking in consideration the', 'information provided by the participating site investigator and commercial manufacturer.', 'The MCW PI will review each SAE submitted on this study, determine if it qualifies as a UPIRSO, and', 'report it to the sIRB.', 'The MCW PI will submit a MedWatch form to Jazz Pharmaceuticals (for their postmarketing reporting)', \"only if the MCW study's SAE is suspected, unexpected, AND serious (SUSAR, must meet all three to\", 'meeting qualifying criteria).', 'If the MCW PI identifies a UPIRSO from a qualifying report on this study that results in a significant', 'finding/recommendation/action (e.g., change in study conduct, consent, study closure, study hold), it is', 'reported in the following manner:', 'The multisite coordinator notifies site principal investigators, site study staff lead contact, the', 'DSMC coordinator, sIRB and Jazz Pharmaceuticals within five calendar days of awareness', 'Participating sites report according to local SOPs.', 'The multisite coordinator emails the DSMC follow-up letter to site principal investigators and', 'Jazz Pharmaceuticals after completion.', 'If the MCW principal investigator identifies a UPIRSO from a report on this study that does not result in a', 'significant finding/recommendation/action (e.g., change in study conduct, consent, study closure, study', 'hold), it is reported in the following manner:', 'The multisite coordinator notifies the DSMC coordinator, sIRB, and Jazz Pharmaceuticals within', 'MCW Protocol No: IIT-Michaelis-OutpatientCPX-351', 'p41', 'Version No.: 3', 'Version Date: 04/15/2020']['MCW', 'OUTPATIENT', 'VYXEOS', 'TRIAL', 'five calendar days of awareness', 'The multisite coordinator does not email the DSMC follow-up letter to site principal investigators', 'and Jazz Pharmaceuticals, unless requested. These letters are available in Box.', '6.9 Reporting Pregnancy', 'All pregnancies (see below) must be reported in an expended manner from after consent to 90 days post', 'last dose.', 'Female subjects who become pregnant during CPX-351 administration and within 90 days post last dose', 'of CPX-351 must be taken off CPX-351 immediately and followed, as per the study calendar. Participating', 'sites should report the pregnancy in OnCore as a grade 3 SAE and email the pdf report to the MCW principal', 'investigator, Multisite Coordinator (via. the Multisite Team Email, who will notify the DSMC, as necessary)', 'and Jazz Pharmaceuticals within 24 hours of staff awareness.', 'If a male subject impregnates his partner during treatment and 90 days post last dose of CPX-351,', 'participating sites should report the pregnancy in OnCore as a grade 3 SAE and email the pdf report', 'to', 'the MCW principal investigator and Multisite Coordinator (via. the Multisite Team Email, who will', 'notify the DSMC, as necessary) within 24 hours of staff awareness.', \"Whenever possible, a pregnancy (for either a subject or male subject's partner, as described above and\", 'according to sIRB policies regarding consent of this partner) should be followed to term, any premature', 'termination reported and the status of the mother and child should be reported after delivery to the', 'Multisite Coordinator (via. the Multisite Team Email) and to Jazz Pharmaceuticals. Data on fetal outcome', 'and breast-feeding are to be collected for regulatory reporting and drug safety evaluation.', '6.10 Protocol Deviations and Overdose', 'Significant deviations are defined, but not limited to, the following:', 'Subject refusal to be admitted, per care team recommendation.', 'Enrolling an ineligible subject.', 'Deviations that impact subject safety or primary objectives.', 'Prohibited medication use.', 'Overdose.', 'Planned deviations are defined as follows:', \"Any temporary protocol deviation that is anticipated to occur, but hasn't occurred yet.\", \"Sites must follow the sIRB's policies regarding acknowledgment prior to deviation initiation.\", 'Significant and/or planned deviations are reported in the following manner:', 'Participating sites enter the deviation into OnCore and email the pdf report to the MCW', 'principal investigator and Multisite Coordinator (via. the Multisite Team Email, who will notify', 'the DSMC, as necessary) within five calendar days of staff awareness', 'Participating sites report to the sIRB according to their policies and send any acknowledgement', 'letters to the Multisite Coordinator (via. the Multisite Team Email).', 'MCW Protocol No: IIT-Michaelis-OutpatientCPX-351', 'p42', 'Version No.: 3', 'Version Date: 04/15/2020']\n\n###\n\n", "completion": "END"}